Current Pharmaceutical Design

William A. Banks  
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108


Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis

Author(s): Catalina Abad and James A. Waschek

Affiliation: 635 Charles E. Young Dr South, Los Angeles CA 90095.


Multiple sclerosis (MS) is a progressive neurodegenerative disease affecting myelin and axons, which is perpetuated by autoreactive lymphocytes and other inflammatory cell types. Because of the multifactorial nature of this disease, therapies targeting a single process may not be sufficient to halt its progression. VIP and PACAP are two neuropeptides shown to regulate multiple aspects of innate and adaptive immunity, and can also act independently on neural cells to promote their survival and regeneration. Animal studies have proven the efficacy of these peptides for the treatment of several models of neural inflammatory disorders, including those which, like MS, have major Th1/Th17 components. In this review, the immunomodulatory actions of VIP and PACAP will be discussed, with particular emphasis on their potential significance in MS.

Keywords: VIP, PACAP, multiple sclerosis, EAE, neuroimmunomodulation, neuropeptides, immunoprivilege, dexamethasone, lipopolysaccharide, ligand flagellin, orchestrate, microglia, granzyme B, tolerogenic, encephalomyelitis, erythroleukemia, mitogen, myelin, glatiramer acetate

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1025 - 1035]
Pages: 11
DOI: 10.2174/138161211795589364